[Transoral robotic surgery of tonsillar squamous cell carcinoma: analysis of 157 cases from five medical centers].

<b>Objective:</b> To explore the clinical application value of transoral robotic surgery (TORS) in the treatment of tonsil squamous cell carcinoma (TSCC). <b>Methods:</b> A retrospective analysis was conducted. The clinical data of 157 TSCC patients were collected who received TORS at five medical centers, namely, the Sun Yat-sen University Cancer Center, Sun Yat-sen Memorial Hospital, Eye Ear Nose and Throat Hospital of Fudan University, the First Affiliated Hospital of China Medical University, and Tongji Hospital of Tongji Medical College, from January 1 2017 to July 31 2022. There were 130 males and 27 females, aged 24-85 years. All patients were followed-up at least for 2 years (2-year group), among them, 99 patients had a follow-up of 3 years (3-year group). The overall survival (OS), progression-free survival (PFS), clinical stage, human papillomavirus (HPV) infection status were analyzed. SPSS 25.0 and SAS 9.4 were used for statistical analysis. <b>Results:</b> The OS and PFS of the 2-year group were 91.7% and 87.9%, respectively. The OS and PFS of the 3-year group were 85.9% and 82.8%, respectively. The prognosis of patients with locally early-stage was better than that of locally advanced patients, with the OS of 94.4% for T1-2 <i>vs</i>. 78.0% for T3 (<i>P</i>=0.005) and the PFS of 91.2% for T1-2 <i>vs</i>. 75.0% for T3 (<i>P</i>=0.011) in the 2-year group; the OS of 91.1% for T1-2 <i>vs</i>. 65.0% for T3 (<i>P</i>=0.004) and the PFS of 88.6% for T1-2 <i>vs</i>. 60.0% for T3 (<i>P</i>=0.002) in the 3-year group; and also, the OS of 90.0% for stage Ⅰ-Ⅱ <i>vs</i>. 79.5% for stage Ⅲ-Ⅳ (<i>P</i>=0.204) and the PFS of 86.7% for stage Ⅰ-Ⅱ <i>vs</i>. 76.9% for stage Ⅲ-Ⅳ (<i>P</i>=0.188) in the 3-year group. The prognosis of HPV-positive TSCC patients was better than that of HPV-negative patients in the 3-year group, with the OS of 90.9% for HPV-positive <i>vs</i>. 80.5% for HPV-negative (<i>P</i>=0.045) and the PFS of 90.9% for HPV-positive <i>vs</i>. 75.6% for HPV-negative (<i>P</i>=0.047). The average time of postoperative tracheal cannula indwelling was 25.1 days. The indwelling rate and average indwelling time of the postoperative nasogastric tube were 94.3% (148/157) and 8.5 days, respectively. <b>Conclusion:</b> TORS has outstanding survival benefits for TSCC patients. HPV-positive TSCC patients have a better prognosis than HPV-negative patients. TORS treatment of TSCC patients has advantages in postoperative recovery and quality of life.